Decoding a New Chapter in Precision Medicine: Personalized Diagnosis and Treatment Innovation Forum Highly Anticipated!
/
Cancer is the most common type of malignant tumor. In China, there are nearly 4 million new cases of malignant tumors each year. As the "King of All Diseases," cancer delivers a catastrophic blow to every affected family, both physically and psychologically. Throughout the history of the fight against cancer, humanity has been dedicated to the diagnosis and treatment of tumors, yet for a long time remained largely helpless. It was not until the advent of modern medicine that therapeutic outcomes for tumors significantly improved. Over the past century, cancer treatment has undergone a transformation from empirical medicine to evidence-based medicine, and further to translational medicine and personalized diagnosis and therapy, resulting in a 65% increase in long-term survival rates for cancer patients.
Since the launch of the Human Genome Project in 1990, DNA sequencing has undergone revolutionary changes in both throughput and cost. The development of new technologies has led some researchers to shift their focus on disease etiology to the molecular level, giving rise to personalized medicine.Personalized diagnosis and treatment are integrated into every stage of lung cancer care, comprehensively driving new breakthroughs in oncology care models.
Currently, personalized cancer therapy has transitioned from an aspirational vision to clinical practice. Precision treatment modalities, such as molecular subtype-based targeted therapy and immunotherapy, have significantly improved survival rates and quality of life for cancer patients. In line with this trend, targeted precision diagnostic methods represented by next-generation sequencing (NGS) technology are gradually moving from research laboratories into practical applications in clinical pathology departments. Recognizing the opportunities brought by personalized diagnosis and treatment to the healthcare market, industry giants have actively established their presence in this fertile field.
What changes has personalized diagnosis and treatment brought to the field of oncology? What preliminary achievements have been made in personalized diagnosis and treatment within oncology to date? What challenges and requirements does the process of personalized diagnosis and treatment pose for corporate product research and development? What is the future direction of personalized diagnosis and treatment in oncology? What opportunities has personalized diagnosis and treatment created for the healthcare market?The Personalized Diagnosis and Treatment Innovation Forum, co-hosted by VB100 and VCBeat, will provide answers by closely following the entire course of tumor diagnosis and treatment, actively introducing the most cutting-edge technological research achievements, and building a bridge of communication among experts, enterprises, investors, and cancer patients.
This conference will focus on the continuous development of China’s personalized diagnosis and treatment industry, promoting the innovative integration of industry, academia, research, and clinical application across the entire process of tumor screening and diagnosis. To this end, we are pleased to share with you in advance several highlights of the forum:
Due to the high heterogeneity of malignant tumors and significant individual variations, tumor cells can vary depending on their location within the body, even in the same cancer patient (intertumor heterogeneity). Furthermore, tumor cells within the same tumor may exhibit subtle or even marked differences (intratumor heterogeneity). Consequently, cancer has become a personalized disease, with varying efficacy and side effects observed among different individuals using the same medication. As a result, personalized medicine has emerged as a major trend in future cancer treatment.
Precision medicine, grounded in next-generation sequencing (NGS), bioinformatics, and artificial intelligence platforms, is dedicated to personalized tumor diagnosis and drug development. It provides support for computer-aided drug design and the development of tumor biomarkers to the company’s small-molecule and large-molecule drug divisions. Building on this foundation, we are comprehensively establishing a comprehensive oncology big database to ultimately achieve precise and personalized cancer treatment.
Now, with advances in gene sequencing technology, tumor sequencing can provide deep insights into changes in patients’ tumor genomes. The sequencing results can help clinicians develop personalized cancer treatment plans based on the molecular characteristics of tumors, rather than adopting a one-size-fits-all approach. Thanks to this progress, personalized medicine has a stronger evidence base. However, significant bottlenecks remain in this field. Precision medicine addresses the diverse health needs of individuals, and finding the balance between standardized diagnostic and therapeutic frameworks and individualized clinical practice will be a central theme in cancer treatment for the foreseeable future. Clinical experts and industry leaders will share their insights in this section.
If cancer is detected early, nearly all cases can be cured or effectively controlled. Therefore, the promotion of precision medicine extends beyond current cancer patients to encompass early prevention and high-risk screening for tumors.
According to current screening guidelines, cancer screening methods are primarily categorized into three types: imaging, endoscopy, and tumor marker screening. These approaches have significant limitations, effective early screening tools are lacking for most cancer types, and patient compliance is generally low. In recent years, with advances in basic research and improvements in PCR techniques, liquid biopsy has emerged as the dominant approach for early cancer detection. Among various liquid biopsy targets, circulating tumor DNA (ctDNA) analysis has demonstrated overwhelming advantages, offering broad clinical utility in early cancer screening, genetic testing for treatment-naïve and drug-resistant cases, real-time monitoring of therapeutic efficacy, and prediction of metastasis and recurrence.
In the field of cancer diagnostics, companion diagnostics for oncology therapeutics have developed rapidly in recent years. Companion diagnostics can identify which patients are most likely to benefit from specific therapeutic products; determine which patients may experience serious adverse effects due to treatment; and monitor treatment response to enable therapy adjustments, thereby improving safety and efficacy. The main technologies currently employed in marketed oncology companion diagnostic products include fluorescent PCR, fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and next-generation sequencing (NGS). At present, fluorescent PCR is the most widely used technology, while NGS is expected to become the future direction for the development of companion diagnostics. Although early screening and diagnostic fields are showing strong momentum, commercial value conversion has not yet been realized. This topic will further invite representatives from pharmaceutical companies to engage in intellectual exchange.
Currently, chemotherapy and targeted therapy are the primary clinical approaches for treating malignant tumors. Gene sequencing technology can identify genetic mutations or abnormal expression; through precise bioinformatics analysis and medical interpretation, the correlation between these mutations and diseases or targeted drug responses can be established. However, gene sequencing lacks compelling experimental evidence. Moreover, only 30%–50% of cancer patients have identifiable relevant genetic mutations, and even when corresponding targeted drugs are available, only approximately 50% of these patients benefit from the treatment. In addition, chemotherapy is significantly limited by the scope of genetic testing. The selection of current chemotherapy regimens relies mainly on clinical guidelines and empirical experience, with a clinical response rate of only 30%.
Front-end Micro-Tumor (PTC) Drug Sensitivity Testing Technology: Compared with traditional testing methods, this technology can accurately reproduce the dynamics, heterogeneity, and drug sensitivity characteristics of patient tumors. The primary tumor culture success rate is 90%, the testing cycle requires only two weeks, and the clinical concordance rate reaches up to 93%.
Beyond early cancer detection and targeted therapy, post-treatment care (also known as follow-up care) is crucial for further improving cancer treatment outcomes. In this regard, the greatest challenge lies in predicting whether and when cancer will recur, as well as preventing its recurrence. With advancing research on circulating tumor DNA (ctDNA), researchers have recognized that detecting minimal residual disease (MRD) can identify certain high-risk patients who still have a potential for cure. This topic will explore the challenges and requirements that detection technologies pose for corporate product research and development, outline future prospects, and invite representatives from relevant enterprises to share their practical experiences.
Driven by advances in medical AI agents, artificial intelligence, and 5G technology, traditional diagnosis and treatment are evolving toward intelligent, personalized care, and the market for intelligent genetic testing is beginning to emerge. Industry giants are aggressively expanding into the field of personalized therapy through mergers and acquisitions. Pharmaceutical leaders are increasingly directing their R&D efforts toward molecular subtyping-based personalized diagnostics and therapeutics, while also prioritizing biotherapies, particularly immune cell therapies. Unlike previous trends in the biopharmaceutical industry, tech giants such as Google, IBM, and Microsoft have also begun to establish a presence in personalized medicine.
Microsoft founder Bill Gates holds a 4% stake in Foundation Medicine, a company specializing in personalized medicine, while Google Ventures, the venture capital arm of Google, owns a 9% stake. Earlier this year, Roche further invested $1.2 billion in Foundation Medicine. Another company backed by Google, 23andMe, is also one of the most representative firms in the gene sequencing sector. Illumina, which commands 70% of the global market for next-generation sequencers, is not only continuing its equipment R&D but also expanding into clinical personalized therapy, including non-invasive prenatal testing and oncology.
Many industry experts believe that this model—spanning from preventive diagnostics and disease trend prediction to big data-driven health management and personalized medicine—can alter the “destiny” imposed by genetic predispositions to disease, and that the next Google or Microsoft will emerge in the broader healthcare sector.
Seizing Industry Momentum to Pioneer the Future of Healthcare. To this end, VB100 and VCBeat aim to bring together clinical experts, leading industry enterprises, and investors to jointly explore the development of personalized diagnosis and treatment based on individual genetic profiles.Through keynote speeches, report releases, and roundtable discussions, we aim to build a specialized platform for seminars on personalized diagnosis and treatment, a hub for industry trend announcements, and a gathering place for top-tier talent in the sector. This initiative not only provides collaboration opportunities for the personalized diagnosis and treatment industry but also offers patients more efficient and cost-effective diagnostic and therapeutic solutions, contributing to the realization of Healthy China.
Editor:Guo Ye
Forum Schedule: Late May to Early June 2022, Day 3
Venue: Shishan International Conference Center, Suzhou, Jiangsu
Forum Organizers: VB100, VCBeat, Artery Orange, VCBeat Institute
● 09:00-09:20
Release of the Industry Report on Clinical Mass Spectrometry
VCBeat
● 09:20-09:40
Nipping Problems in the Bud: NGP + Tumor Microenvironment Research, Starting from the “Micro” to Facilitate Precision Medicine (Proposed)
Kuoran Genomics
● 09:40-10:00
(Proposed) Development and Application Prospects of ctDNA Methylation Sequencing in the Field of Early Cancer Screening
Yan Linghua | Chairman, CEO, and Founder of Tree Genetics
● 10:00-10:20
(Proposed) Development of Companion Diagnostic Products for Targeted Therapies in Future Clinical Diagnosis and Treatment Scenarios
Wang Xinzhu | Vice President, Chen'an Biomedical
● 10:20-10:40
Widespread Application of New Technologies: How to Improve the Clinical Utility of Front-End Micro-Tumor (PTC) Drug Sensitivity Testing? (Proposed)
Zhang Hanshuo | General Manager, Cornerstone Life
● 10:40-11:00
Prospects and Challenges of MRD Testing in the Clinical Application for Solid Tumors—Taking Lung Cancer as an Example (Draft)
Burning Rock Biotech
● 11:00-11:20
Opportunities and Challenges for Personalized Diagnosis and Treatment in the Era of Genomic Big Data (Proposed)
Top-Tier Domestic Institutional Investors
● 11:20-12:00
Personalized for Life: Precision Oncology Opens a New Chapter in the Future of Cancer Treatment (Proposed)
Yan Linghua | Chairman, CEO, and Founder of Tree Genetics
Ding Fang | CEO of Dajian Bio
Experts from relevant domestic associations / Top-tier investment institutions / Founders of innovative enterprises
● Mapping the Industry Landscape, Telling China’s Story: The 2022 Top 100 Future Healthcare Companies Conference Held with Great Momentum
From “Eye of the Storm,” “Species Big Bang,” “Tide ING,” and “New Growth of Life” to “The Calculation of Life”; from 20 speakers, 150 companies, and 400 attendees at the inaugural event to a cumulative total of over 1,000 domestic and international speakers, more than 5,000 participating companies, over 20,000 attendees, and 5 million+ impressions... The Top 100 Future Healthcare Conference has grown alongside China’s medical and health industry, continuously expanding to become the largest and most information-rich summit integrating industry and capital within China’s healthcare innovation sector.
The 6th Future Healthcare Top 100 Conference will be held at the Shishan International Convention Center in Suzhou, Jiangsu Province. This year, we will collaborate with embassies from various countries to jointly host a global roadshow for innovative healthcare projects. Embarking with a renewed vision, we will focus on “China’s Story,” ground ourselves in innovation, faithfully document the trajectory of the global healthcare industry, and identify leading innovative enterprises in the sector. We will analyze industry hotspots and interpret future development trends in the healthcare industry from five dimensions: policy orientation, technological frontiers, capital perspectives, industrial innovation, and market demand, thereby driving transformation in the innovative healthcare industry. Our aim is to gather core industry forces, promote transformation in the innovative healthcare sector, and build a comprehensive exchange and matchmaking platform for the entire medical and health industry chain.
● Converging Multiple Highlights to Create the 2022 Premier Healthcare Industry Event in China
Top-Tier Guest Lineup— Led by Academicians and Scientists300+ Industry LeadersBringing three days of the most cutting-edge medical technology, industry trends, and business innovation
Business Wisdom of Industry Leaders——In ChinaStrategic Launch by Benchmark Listed Companies, Gaining Insights into the Future of the Industry and the Innovation Landscape
Global Perspective and Overseas Resources— FromUnited Kingdom, Canada, Belgium...and the industrial development trends and capital markets of multiple countries, linking high-quality overseas technological innovation projects
In-Depth Insights into Niche Sectors——Major Announcement6 Industry Research Series Reports, Exploring Development Opportunities and Innovative Cases in Niche Fields
Gathering Core Forces for the Future of Healthcare——Release5 Top 100 Lists and 2 Awards, bringing together 1,000+ unicorns and high-potential innovative enterprises to jointly explore the path of innovative development
A Forward-Looking Capital Perspective——100+ including GP/LP/CVC/VC/PE/FA, etc.Financial Institutions as Forward-Looking Investors: Sensing the Direction of Capital Heat in the Industry
/
Conference Dates: Late May or Early June 2022
Venue: Shishan International Conference Center, Suzhou, China
Limited-Time Offer: Conference All-Access Pass
Purchase Channels:Search for the “VB100” mini program on WeChat to make a purchase.
Two types of general admission tickets are available for public sale at this conference:
899 Yuan [VB100 All-Access Pass, Meals Not Included]¥1,299 [VB100 All-Access Pass with Meals]Limited-Time Offer · Conference All-Access Pass¥630 off the original price, now as low as ¥269Onset:
Your Trust Entitles You to the Following Benefits:
1. All-Access Pass for Forum, Exhibition, and Interactive Activities (Separate registration required for certain segments such as LPGP)
2. On-Site Resource Coordination and Exchange Group
3. Guest-authorized PPTs, conference proceedings, public reports, and other restricted materials
4. Lunch vouchers during the conference (only for tickets including meals)
Special Note:
1. Duration of this limited-time offerUpdates on Key Milestones from Today Until the Next Meeting;
2. Ticket prices will be adjusted as information regarding the conference theme, speakers, topics, and exhibitors is unveiled,For every 100 yuan increase, until the original price is restored;
3、After this limited-time offer ends,Ticket prices will rise to 369 yuan.Qi
Scan the QR code to register for the 2022·6th Future Healthcare Top 100 Conference
Inquiry Regarding the 2022 Future Healthcare Top 100 Conference
